Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Other Operating Expenses (2023 - 2024)

Zentalis Pharmaceuticals (ZNTL) has 3 years of Other Operating Expenses data on record, last reported at -$4000.0 in Q1 2025.

  • For Q1 2025, Other Operating Expenses changed N/A year-over-year to -$4000.0; the TTM value through Sep 2025 reached $3.7 million, changed N/A, while the annual FY2024 figure was $3.7 million, 91.8% down from the prior year.
  • Other Operating Expenses reached -$4000.0 in Q1 2025 per ZNTL's latest filing, down from $3.7 million in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $45.6 million in Q2 2023 and bottomed at -$4000.0 in Q1 2025.
  • Average Other Operating Expenses over 3 years is $16.4 million, with a median of $3.7 million recorded in 2024.